Drug Database
Back to search

Finland· FI-REL-REL58480

Xevudy

A sotrovimab product containing sotrovimab, registered in Finland by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 7 of our 19 countries.

ATC J06BD05

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedXevudyATCJ06BD05REGISTER NO.FI-REL-REL58480PACKS LISTED0CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about sotrovimabAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Sotrovimab is registered in 7 of 19 countries.

Countries holding a registration under ATC J06BD05 (sotrovimab), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 5 of them publish a price we can compare per daily dose
Search sotrovimab products by name

Sotrovimab · ATC J06BD05

7 / 19 countries

  • Belgiumprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Polandprice
  • Spainprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Sotrovimab
Manufacturer
GlaxoSmithKline Trading Services Limited
Country
Finland (FI)
ATC code
J06BD05
ATC class
Sotrovimab
Defined daily dose
0.5 g, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Sotrovimab in 6 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All sotrovimab products

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2f1ae5a5-4810-4cc4-bd6a-03471833679a
GET /v1/drugs/2f1ae5a5-4810-4cc4-bd6a-03471833679a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "0.5",
  "form": "infuusiokonsentraatti, liuosta varten",
  "route": "Laskimoon",
  "ddd_unit": "g",
  "strength": "500 mg",
  "atc_label": "sotrovimabi",
  "ma_number": null,
  "auth_status": "Myyntilupa peruuntunut",
  "eu_ma_number": "EU/1/21/1562/001",
  "fimea_rel_id": "REL58480",
  "authorised_at": "2021-12-17"
}
API referenceMCP serverPlans

See everything about sotrovimab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console